LT2934145T - Histono demetilazės inhibitoriai - Google Patents

Histono demetilazės inhibitoriai

Info

Publication number
LT2934145T
LT2934145T LTEP13866465.1T LT13866465T LT2934145T LT 2934145 T LT2934145 T LT 2934145T LT 13866465 T LT13866465 T LT 13866465T LT 2934145 T LT2934145 T LT 2934145T
Authority
LT
Lithuania
Prior art keywords
histone demethylase
demethylase inhibitors
inhibitors
histone
demethylase
Prior art date
Application number
LTEP13866465.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Toufike Kanouni
Jeffrey Alan Stafford
James Marvin Veal
Michael Brennan Wallace
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of LT2934145T publication Critical patent/LT2934145T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
LTEP13866465.1T 2012-12-19 2013-12-19 Histono demetilazės inhibitoriai LT2934145T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739521P 2012-12-19 2012-12-19
US201361792930P 2013-03-15 2013-03-15
PCT/US2013/076666 WO2014100463A1 (en) 2012-12-19 2013-12-19 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
LT2934145T true LT2934145T (lt) 2018-02-26

Family

ID=50931614

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13866465.1T LT2934145T (lt) 2012-12-19 2013-12-19 Histono demetilazės inhibitoriai

Country Status (17)

Country Link
US (4) US9617242B2 (enExample)
EP (1) EP2934145B1 (enExample)
JP (1) JP6256772B2 (enExample)
AU (1) AU2013361255B2 (enExample)
CA (1) CA2895355A1 (enExample)
CY (1) CY1119901T1 (enExample)
DK (1) DK2934145T3 (enExample)
ES (1) ES2658597T3 (enExample)
HR (1) HRP20180067T1 (enExample)
HU (1) HUE037312T2 (enExample)
LT (1) LT2934145T (enExample)
PL (1) PL2934145T3 (enExample)
PT (1) PT2934145T (enExample)
RS (1) RS56821B1 (enExample)
SI (1) SI2934145T1 (enExample)
SM (1) SMT201800070T1 (enExample)
WO (1) WO2014100463A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881554C (en) 2012-08-22 2022-01-04 Cornell University Methods for inhibiting fascin
US20150203453A1 (en) 2012-10-02 2015-07-23 Epitherapeutics Aps Inhibitors of histone demethylases
WO2014100463A1 (en) 2012-12-19 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
ES2718495T3 (es) 2012-12-21 2019-07-02 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
JP6514117B2 (ja) 2013-02-27 2019-05-15 エピセラピューティクス アーペーエス ヒストン脱メチル化酵素の阻害剤
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
CN105980386B (zh) 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
DK3107902T3 (da) * 2014-02-20 2021-05-03 Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec Forbindelser og fremgangsmåder til at hæmme fascin
SG11201610813TA (en) 2014-06-25 2017-01-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
CA2957947A1 (en) 2014-08-27 2016-03-03 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
AU2015317806A1 (en) 2014-09-17 2017-04-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9758517B2 (en) 2014-09-17 2017-09-12 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10059687B2 (en) 2015-12-28 2018-08-28 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN105601555B (zh) * 2016-03-14 2018-07-31 苏州大学 一种制备硝基吲哚衍生物的方法
ES2921009T3 (es) * 2016-03-15 2022-08-16 Celgene Quanticel Res Inc Inhibidores de desmetilasas de histonas
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
PT3507276T (pt) 2016-09-02 2022-01-11 Gilead Sciences Inc Compostos moduladores do recetor de tipo toll
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
WO2018073828A1 (en) * 2016-10-20 2018-04-26 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Dna primase and gyrase inhibitors
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
WO2018149986A1 (en) * 2017-02-16 2018-08-23 Oryzon Genomics, S.A. 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’-環二核苷酸
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350871B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. 2’3’-環状ジヌクレオチドおよびそのプロドラッグ
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
MY208114A (en) 2019-09-30 2025-04-16 Gilead Sciences Inc Hbv vaccines and methods treating hbv
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112023002164A2 (pt) 2020-08-07 2023-03-14 Gilead Sciences Inc Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2023386923A1 (en) 2022-11-21 2025-05-15 Nippon Shinyaku Co., Ltd. Compound serving as ddr1 kinase inhibitor, and medicine
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593349B2 (en) * 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
EP1537087B1 (fr) * 2002-09-05 2012-11-28 Aventis Pharma S.A. Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
FR2882361A1 (fr) * 2005-02-22 2006-08-25 Aventis Pharma Sa Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation
ATE456392T1 (de) * 2006-07-20 2010-02-15 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
SG183049A1 (en) * 2007-07-20 2012-08-30 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
CA2745004C (en) 2008-11-28 2014-07-15 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
ES2534804T3 (es) * 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014100463A1 (en) 2012-12-19 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
AU2013361255B2 (en) 2017-01-05
EP2934145B1 (en) 2017-11-15
US10336727B2 (en) 2019-07-02
HRP20180067T1 (hr) 2018-02-23
AU2013361255A1 (en) 2015-07-09
US20140171432A1 (en) 2014-06-19
WO2014100463A1 (en) 2014-06-26
PT2934145T (pt) 2018-02-13
CA2895355A1 (en) 2014-06-26
PL2934145T3 (pl) 2018-04-30
US9617242B2 (en) 2017-04-11
SMT201800070T1 (it) 2018-03-08
US20180305336A1 (en) 2018-10-25
JP6256772B2 (ja) 2018-01-10
DK2934145T3 (en) 2018-02-05
SI2934145T1 (en) 2018-03-30
JP2016503799A (ja) 2016-02-08
RS56821B1 (sr) 2018-04-30
US20170174656A1 (en) 2017-06-22
HUE037312T2 (hu) 2018-08-28
US10040779B2 (en) 2018-08-07
EP2934145A1 (en) 2015-10-28
US8969343B2 (en) 2015-03-03
CY1119901T1 (el) 2018-06-27
EP2934145A4 (en) 2016-06-29
ES2658597T3 (es) 2018-03-12
US20160060247A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
ZA201505007B (en) Histone demethylase inhibitors
LT2934145T (lt) Histono demetilazės inhibitoriai
IL253259B (en) Inhibitors of histone demethylases
LT2970211T (lt) Histono demetilazės inhibitoriai
IL237355B (en) Glucosylceramide synthase inhibitors
ZA201407554B (en) Dna-pk inhibitors
EP2680694A4 (en) INHIBITORS OF HISTONE DEACETYLASE
IL235919A0 (en) inhibitors of fbxo3
AU2019222801A1 (en) Glucosylceramide synthase inhibitors
AU2018200675A1 (en) Glucosylceramide synthase inhibitors
GB201223308D0 (en) Enzyme inhibitors
GB201120474D0 (en) Inhibitors